AFT Pharmaceuticals Limited

NZSE:AFT Lagerbericht

Marktkapitalisierung: NZ$281.0m

AFT Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

AFT Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 16.5% bzw. 11.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 19.5% betragen.

Wichtige Informationen

16.5%

Wachstumsrate der Gewinne

16.4%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum47.8%
Wachstumsrate der Einnahmen11.4%
Zukünftige Eigenkapitalrendite19.5%
Analystenabdeckung

Low

Zuletzt aktualisiert01 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Recent updates

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26
It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25
AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

May 22
Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Oct 17
Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

May 23
Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

Dec 01
Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30
We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02
With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20
Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13
A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23
Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02
Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12
Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21
AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Gewinn- und Umsatzwachstumsprognosen

NZSE:AFT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (NZD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/20272762725203
3/31/20262512417163
3/31/20252171512103
3/31/2024195161929N/A
12/31/2023185131221N/A
9/30/202317511413N/A
6/30/202316611312N/A
3/31/202315711212N/A
12/31/202214914412N/A
9/30/202214117613N/A
6/30/202213518714N/A
3/31/202213020914N/A
12/31/202112515712N/A
9/30/202112011510N/A
6/30/2021116906N/A
3/31/20211138-51N/A
12/31/20201105-43N/A
9/30/20201073-26N/A
6/30/20201077310N/A
3/31/202010612815N/A
12/31/201910011712N/A
9/30/2019941159N/A
6/30/201989415N/A
3/31/201985-3-21N/A
12/31/201884-7-5-1N/A
9/30/201883-11-8-4N/A
6/30/201882-12-10-6N/A
3/31/201881-14-12-9N/A
12/31/201779-14N/A-13N/A
9/30/201776-14N/A-16N/A
6/30/201773-16N/A-18N/A
3/31/201769-18N/A-19N/A
12/31/201667-18N/A-20N/A
9/30/201664-18N/A-21N/A
6/30/201664-16N/A-17N/A
3/31/201664-13N/A-14N/A
12/31/201563-13N/A-12N/A
9/30/201562-13N/A-10N/A
6/30/201559-13N/A-11N/A
3/31/201556-13N/A-13N/A
3/31/201449-1N/A0N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: AFTDas prognostizierte Gewinnwachstum (16.5% pro Jahr) liegt über der Sparquote (3%).

Ertrag vs. Markt: AFTDie Erträge des Unternehmens (16.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (15.4% pro Jahr).

Hohe Wachstumserträge: AFTDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: AFTDie Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt NZ (4.4% pro Jahr).

Hohe Wachstumseinnahmen: AFTDie Einnahmen des Unternehmens (11.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: AFTDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (19.5%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y